[go: up one dir, main page]

DE69909747D1 - Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen - Google Patents

Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen

Info

Publication number
DE69909747D1
DE69909747D1 DE69909747T DE69909747T DE69909747D1 DE 69909747 D1 DE69909747 D1 DE 69909747D1 DE 69909747 T DE69909747 T DE 69909747T DE 69909747 T DE69909747 T DE 69909747T DE 69909747 D1 DE69909747 D1 DE 69909747D1
Authority
DE
Germany
Prior art keywords
asparaginase
treatment
pharmaceutical composition
hiv infections
containing peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69909747T
Other languages
English (en)
Other versions
DE69909747T2 (de
Inventor
I Avramis
Lewis Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of DE69909747D1 publication Critical patent/DE69909747D1/de
Application granted granted Critical
Publication of DE69909747T2 publication Critical patent/DE69909747T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69909747T 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen Expired - Fee Related DE69909747T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7406698P 1998-02-09 1998-02-09
US74066P 1998-02-09
PCT/US1999/002480 WO1999039732A1 (en) 1998-02-09 1999-02-09 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections

Publications (2)

Publication Number Publication Date
DE69909747D1 true DE69909747D1 (de) 2003-08-28
DE69909747T2 DE69909747T2 (de) 2004-04-15

Family

ID=22117505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69909747T Expired - Fee Related DE69909747T2 (de) 1998-02-09 1999-02-09 Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen

Country Status (10)

Country Link
EP (1) EP1053012B1 (de)
JP (1) JP2002502826A (de)
AT (1) ATE245444T1 (de)
AU (1) AU752434B2 (de)
CA (1) CA2319356A1 (de)
DE (1) DE69909747T2 (de)
DK (1) DK1053012T3 (de)
ES (1) ES2203072T3 (de)
WO (1) WO1999039732A1 (de)
ZA (1) ZA991029B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4030200A (en) * 1999-04-02 2000-10-23 Children's Hospital Of Los Angeles Use of asparaginase and glutaminase to treat autoimmune disease and graft versushost disease
JP2003506409A (ja) * 1999-08-06 2003-02-18 アヴェンティス ファーマシューティカルズ インコーポレイテッド Ｈｉｖ感染の治療用組成物及び方法
KR100777195B1 (ko) 2000-04-03 2007-11-19 산텐 세이야꾸 가부시키가이샤 송달성 물질 및 이를 이용한 약물 송달 시스템
CN100544718C (zh) 2001-04-20 2009-09-30 维奥恩药品公司 化合物在制备抗病毒剂中的用途
ES2381998T3 (es) 2002-11-26 2012-06-04 The University Of Chicago Prevención y tratamiento de trastornos eipiteliales mediados por microbios
WO2006029507A1 (en) * 2004-09-13 2006-03-23 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of feline calicivirus replication by asparaginase
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2015033344A1 (en) * 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
CA3084030C (en) * 2017-11-29 2023-03-21 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
CN115671102A (zh) * 2022-11-17 2023-02-03 中国科学院大学 3-ap在制备抑制痘病毒的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (fr) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
US6251388B1 (en) * 1997-06-09 2001-06-26 Childrens Hospital Los Angeles Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence

Also Published As

Publication number Publication date
EP1053012B1 (de) 2003-07-23
ZA991029B (en) 1999-09-30
DK1053012T3 (da) 2003-11-17
DE69909747T2 (de) 2004-04-15
WO1999039732A1 (en) 1999-08-12
EP1053012A1 (de) 2000-11-22
CA2319356A1 (en) 1999-08-12
ES2203072T3 (es) 2004-04-01
ATE245444T1 (de) 2003-08-15
AU2658499A (en) 1999-08-23
AU752434B2 (en) 2002-09-19
JP2002502826A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
BG100455A (en) Hiv protease inhibitors
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
ATE252081T1 (de) Neue hiv-protease-inhibitoren
DE69830751D1 (de) Polyaromatische Verbindungen zur Behandlung von Herpes-Infektionen
LV12719A (lv) Benzoxazinones as inhibitors of hiv reverse transcriptase
DE69814049D1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
ATE215952T1 (de) Hiv-proteaseinhibitoren
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ES2132383T3 (es) Inhibidores de proteasa hiv.
EE9700165A (et) Ühendite kombinatsioon, meetod ja farmatseutiline kompositsioon HIV proteaasi ja HIV pöördtranskriptaasi inhibeerimiseks ning HIV infektsiooni vältimiseks või raviks, või AIDS-i või ARC raviks
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
GB9930768D0 (en) Composition
DE69838980D1 (de) Kombination von product r mit einem antiviralen mittel in der behandlung von hiv infektionen
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
NO20024522D0 (no) Sammensetninger med anti-hiv-aktivitet
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
DK0774969T3 (da) HIV-proteaseinhibitor kombination
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
TR199902508T2 (xx) HIV proteaz inhibit�rleri.
RU93055681A (ru) Ингибиторы вич-протеазы, способ их получения, их использование в фармкомпозициях

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee